Dual-Targeted Protein MRI Contrast Agent for Early Detection of Micrometastases

Abstract

Tumor metastasis accounts for the major portion of cancer-related deaths. Magnetic resonance imaging (MRI) is a valuable imaging modality for tumor diagnosis in clinical applications, offering detailed soft tissue images with excellent spatial resolution and good biosafety. However, the low sensitivity and the lack of specificity to disease sites limit the application of MRI contrast agents in early and precise detection of small primary and metastatic cancers. Therefore, there is an urgent need for innovative MRI contrast agents with enhanced relaxivity, target ability, and pharmacokinetics to improve imaging sensitivity and widen the detection window in the meantime. Here, we reported a dual-targeting protein MRI contrast agent (EPR-DTPA-Gd) fused by a nanobody against epidermal growth factor receptor 1 (EGFR), integrin α_vβ₃-binding cyclic nonapeptide, and elastin-like polypeptide. We found that this protein contrast agent exhibited high sensitivity and specificity for the tumor overexpressed EGFR and integrin α_vβ₃ in MRI. Furthermore, EPR-DTPA-Gd had high longitudinal relaxation rate (r₁) (68.76 mM⁻¹ s⁻¹ per molecule) and an improved pharmacokinetics behavior for tumor imaging. Using T1-weighted imaging, EPR-DTPA-Gd successfully detected a series of early metastases with the smallest 0.012 mm² (213 µm × 58 µm) in a liver metastasis model of human cervical carcinoma HeLa cells, which cannot be detected by the clinically approved T1-weighted contrast agent. The heightened detection sensitivity intrinsic to EPR-DTPA-Gd facilitates precise imaging of tumor lesions, supporting sophisticated image-guided interventions and early management in high-risk patient cohorts.

Keywords

dual-targeted / magnetic resonance imaging / protein contrast agents / tumor detection

References

[1] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74 (2024): 12-49.

[2] H. Dillekas, M. S. Rogers, and O. Straume, “Are 90% of Deaths From Cancer Caused by Metastases?,” Cancer Medicine 8 (2019): 5574-5576.

[3] Z. Lu, Y. Chen, D. Liu, et al., “The Landscape of Cancer Research and Cancer Care in China,” Nature Medicine 29 (2023): 3022-3032.

[4] D. Crosby, S. Bhatia, K. M. Brindle, et al., “Early Detection of Cancer,” Science 375 (2022): eaay9040.

[5] Y. Ming, N. Wu, T. Qian, et al., “Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer,” Frontiers in Oncology 10 (2020): 1301.

[6] J. Ge, Q. Zhang, J. Zeng, Z. Gu, and M. Gao, “Radiolabeling Nanomaterials for Multimodality Imaging: New Insights Into Nuclear Medicine and Cancer Diagnosis,” Biomaterials 228 (2020): 119553.

[7] B. R. Smith and S. S. Gambhir, “Nanomaterials for in Vivo Imaging,” Chemical Reviews 117 (2017): 901-986.

[8] J. Qiao, S. Xue, F. Pu, et al., “Molecular Imaging of EGFR/HER2 Cancer Biomarkers by Protein MRI Contrast Agents,” Journal of Biological Inorganic Chemistry 19 (2013): 259-270.

[9] K. Glunde, D. Artemov, M.-F. Penet, M. A. Jacobs, and Z. M. Bhujwalla, “Magnetic Resonance Spectroscopy in Metabolic and Molecular Imaging and Diagnosis of Cancer,” Chemical Reviews 110 (2010): 3043-3059.

[10] G. Solomakha, A. Andreychenko, P.-F. v. d. Moortele, et al., “A Coaxial RF Applicator for Ultra-High Field Human MRI,” IEEE Transactions on Bio-Medical Engineering 66 (2019): 2848-2854.

[11] J. Davies, P. Siebenhandl-Wolff, F. Tranquart, P. Jones, and P. Evans, “Gadolinium: Pharmacokinetics and Toxicity in Humans and Laboratory Animals Following Contrast Agent Administration,” Archives of Toxicology 96 (2022): 403-429.

[12] C. Klein, U. Brinkmann, J. M. Reichert, and R. E. Kontermann, “The Present and Future of Bispecific Antibodies for Cancer Therapy,” Nature Reviews Drug Discovery 23 (2024): 301-319.

[13] M. E. Goebeler, G. Stuhler, and R. Bargou, “Bispecific and Multispecific Antibodies in Oncology: Opportunities and Challenges,” Nature Reviews Clinical Oncology 21 (2024): 539-560.

[14] S. Turajlic, A. Sottoriva, T. Graham, and C. Swanton, “Resolving Genetic Heterogeneity in Cancer,” Nature Reviews Genetics 20 (2019): 404-416.

[15] E. R. Verhaar, A. W. Woodham, and H. L. Ploegh, “Nanobodies in Cancer,” Seminars in Immunology 52 (2021): 101425.

[16] W. Zeng, L. Wu, Y. Ishigaki, et al., “An Activatable Afterglow/MRI Bimodal Nanoprobe With Fast Response to H2 S for In Vivo Imaging of Acute Hepatitis,” Angewandte Chemie Int. Ed. 61 (2022): e202111759.

[17] L.-J. Luo, X.-M. Liu, X. Zhang, et al., “Quantitative Detection of in Vivo Aggregation Degree for Enhanced M2 Macrophage MR Imaging,” Nano Letters 22 (2022): 1694-1702.

[18] D. Li, M. Kirberger, J. Qiao, et al., “Protein MRI Contrast Agents as an Effective Approach for Precision Molecular Imaging,” Investigative Radiology 59 (2024): 170-186.

[19] M. Salarian, H. Yang, R. C. Turaga, et al., “Precision Detection of Liver Metastasis by Collagen-Targeted Protein MRI Contrast Agent,” Biomaterials 224 (2019): 119478.

[20] M. Salarian, R. C. Turaga, S. Xue, et al., “Early Detection and Staging of Chronic Liver Diseases With a Protein MRI Contrast Agent,” Nature Communications 10 (2019): 4777.

[21] H. Zhao, H. Zhao, Y. Jiao, et al., “Biosynthetic Molecular Imaging Probe for Tumor-Targeted Dual-Modal Fluorescence/Magnetic Resonance Imaging,” Biomaterials 256 (2020): 120220.

[22] R. Yan, Y. Hu, F. Liu, et al., “Activatable NIR Fluorescence/MRI Bimodal Probes for in Vivo Imaging by Enzyme-Mediated Fluorogenic Reaction and Self-Assembly,” Journal of the American Chemical Society 141 (2019): 10331-10341.

[23] S. Xue, H. Yang, J. Qiao, et al., “Protein MRI Contrast Agent With Unprecedented Metal Selectivity and Sensitivity for Liver Cancer Imaging,” Proceedings of the National Academy of Sciences of the United States of America 112 (2015): 6607-6612.

[24] L. Ding, C. Tian, S. Feng, et al., “Small Sized EGFR1 and HER2 Specific Bifunctional Antibody for Targeted Cancer Therapy,” Theranostics 5 (2015): 378-398.

[25] J. S. Desgrosellier and D. A. Cheresh, “Integrins in Cancer: Biological Implications and Therapeutic Opportunities,” Nature Reviews Cancer 10 (2010): 9-22.

[26] W. Chen, Y. Yuan, C. Li, H. Mao, B. Liu, and X. Jiang, “Modulating Tumor Extracellular Matrix by Simultaneous Inhibition of Two Cancer Cell Receptors,” Advanced Materials 34 (2022): e2109376.

[27] X. Xin, H. Sha, J. Shen, B. Zhang, B. Zhu, and B. Liu, “Coupling GdDTPA With a Bispecific, Recombinant Protein Anti-EGFRiRGD Complex Improves Tumor Targeting in MRI,” Oncology Reports 35 (2016): 3227-3235.

[28] A. Rondon, S. Mahri, F. Morales-Yanez, M. Dumoulin, and R. Vanbever, “Protein Engineering Strategies for Improved Pharmacokinetics,” Advanced Functional Materials 31 (2021): 2101633.

[29] R. Tenchov, A. K. Sapra, J. Sasso, et al., “Biomarkers for Early Cancer Detection: A Landscape View of Recent Advancements, Spotlighting Pancreatic and Liver Cancers,” ACS Pharmacology & Translational Science 7 (2024): 586-613.

[30] R. I. Nicholson, J. M. Gee, and M. E. Harper, “EGFR and Cancer Prognosis,” European Journal of Cancer 37 (2001): S9-S15.

[31] J. S. Desgrosellier, L. A. Barnes, D. J. Shields, et al., “An Integrin Alpha(v)Beta(3)-c-Src Oncogenic Unit Promotes Anchorage-Independence and Tumor Progression,” Nature Medicine 15 (2009): 1163-1169.

[32] J. Wahsner, E. M. Gale, A. Rodriguez-Rodriguez, and P. Caravan, “Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers,” Chemical Reviews 119 (2019): 957-1057.

[33] Y. Lu, Z. Liang, J. Feng, et al., “Facile Synthesis of Weakly Ferromagnetic Organogadolinium Macrochelates-Based T1 -Weighted Magnetic Resonance Imaging Contrast Agents,” Advanced Science 10 (2022): e2205109.

[34] C. Liu, X. Liu, Z. Wei, et al., “Amorphous Albumin Gadolinium-Based Nanoparticles for Ultrahigh-Resolution Magnetic Resonance Angiography,” ACS Applied Materials & Interfaces 16, 8 (2024): 9702-9712.

RIGHTS & PERMISSIONS

2025 The Author(s). Aggregate published by SCUT, AIEI, and John Wiley & Sons Australia, Ltd.